Advancing Science. Improving Connections.

Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.

Our Patients

Focusing on the unmet medical needs of patients with rare disorders and their families

Our Company

Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases

Our Pipeline

Pioneering cannabinoid treatments for neuropsychiatric conditions

Latest News

12.17

Zynerba Pharmaceuticals Provides Clinical Update and Announces Two New Clinical Indications

12.12

Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment with ZYN002

11.20

Zynerba Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference

10.11

Zynerba Pharmaceuticals to Present at the 2018 BIO Investor Forum